Role of pemetrexed in advanced non-small-cell lung cancer: Meta-analysis of randomized controlled trials, with histology subgroup analysis

Current Oncology

Volumn 19, Issue 1, 2012, Pages

  Al Saleh, K ^a   Quinton, C ^b   Ellis, P M ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b CREDIT VALLEY HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Meta analysis; NSCLC; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PEMETREXED; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 84856833219     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.891     Document Type: Article

References (26)

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2009. Toronto, ON: Canadian Cancer Society; 2009: 13-14.
2. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Ver. 2.2012. Fort Washington, PA: nccn; 2011. [Available online at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (free registration required); cited December 9, 2011]
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
5. De Marinis F, De Petris L. Pemetrexed in second-line treatment of non-small-cell lung cancer. Oncology (Williston Park) 2004;18(suppl 8):38-42.
6. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
7. Jones RJ, Twelves CJ. Pemetrexed: a multitargeted antifolate (Alimta, LY-231514). Expert Rev Anticancer Ther 2002;2:13-22.
8. Calvert AH. Biochemical pharmacology of pemetrexed. Oncology (Williston Park) 2004;18(suppl 8):13-17.
9. McKibbon KA, Wilczynski NL, Haynes RB, on behalf of the Hedges Team. Retrieving randomized controlled trials from medline: a comparison of 38 published search filters. Health Info Libr J 2009;26:187-202.
10. George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst 2007;99:98-9.
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
13. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase iii study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24.
14. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
15. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase ii trial of pemetrexed (p) + carboplatin (cb) ± enzastaurin (e) versus docetaxel (d) + cb as first-line treatment of patients (pts) with stage iiib/iv non-small cell lung cancer (nsclc) [abstract 8037]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34353; cited December 7, 2011]
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Ver. 5.0.2. Chichester, U.K.: John Wiley and Sons; 2009.
17. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-8.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. [Erratum in: Stat Med 2004;23:1817]
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
20. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-smallcell lung cancer. J Clin Oncol 2004;22:3852-9.
21. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
22. Tam VC, Hotte SJ. Consistency of phase iii clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. J Clin Oncol 2008;26:2205-11.
23. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14:253-63.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
25. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
26. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.